Loading
Blaze Bioscience
Blaze Bioscience is a Seattle company whose 'Tumor Paint', tozuleristide, is a scorpion-toxin peptide linked to a dye that lights up tumour tissue during surgery; it reached phase 3 in children's brain tumours.
Also called: Blaze Bioscience Inc.Blaze Bioscience, Inc.
Overview
Blaze Bioscience, founded in 2010 in Seattle from the work of Jim Olson at Fred Hutchinson Cancer Center, developed tozuleristide (BLZ-100), a chlorotoxin-derived peptide conjugated to the near-infrared dye indocyanine green that binds tumour cells and shows surgeons where tumour ends. It was taken into a phase 3 trial in paediatric central nervous system tumours, registered on ClinicalTrials.gov under Blaze as lead sponsor.
Connected
6Similar pages
- CompanyPregLem
- Companyphotonamic
Shares Fluorescence-guided surgery, Pivotal (registrational) trial, Clinical trial.
- CompanyAgennix
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanySBI Pharmaceuticals
Shares Fluorescence-guided surgery, Pivotal (registrational) trial, Clinical trial.
- InstitutionSeattle Children's Hospital
Shares Fred Hutchinson Cancer Center, Childhood cancers (all types).
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
blazebioscience.com · 1
ClinicalTrials.gov · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/